STAAR Surgical Company (STAA) P/E Ratio History
Deep ValueTrading at -18.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 1994–2024
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, STAAR Surgical Company (STAA) trades at a price-to-earnings ratio of -18.0x, with a stock price of $29.12 and trailing twelve-month earnings per share of $-0.41.
The current P/E is 109% below its 5-year average of 198.2x. Over the past five years, STAA's P/E has ranged from a low of 62.2x to a high of 653.6x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, STAA trades at a 181% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, STAA trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our STAA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
STAA Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
STAA P/E vs Peers
Dental and vision care devices peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $13B | 32.2 | - | +1% | |
| $7B | 30.5 | - | -22% | |
| $3B | 16.2 | - | +382%Best | |
| $50B | 47.7 | 6.74 | -74% | |
| $17B | 30.5 | - | -25% | |
| $154B | 11.6Lowest | 0.39Best | +134% | |
| $67B | 23.3 | - | +55% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
STAA Historical P/E Data (1994–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q3 | Sep 27 2024 | $37.23 | $0.44 | 84.3x | -90% |
| FY2024 Q2 | Jun 28 2024 | $47.61 | $0.34 | 140.3x | -83% |
| FY2024 Q1 | Mar 29 2024 | $38.28 | $0.31 | 123.8x | -85% |
| FY2023 Q4 | Dec 29 2023 | $31.21 | $0.43 | 72.2x | -91% |
| FY2023 Q3 | Sep 29 2023 | $40.18 | $0.39 | 102.4x | -88% |
| FY2023 Q2 | Jun 30 2023 | $52.57 | $0.50 | 104.1x | -88% |
| FY2023 Q1 | Mar 31 2023 | $63.95 | $0.64 | 99.2x | -88% |
| FY2022 Q4 | Dec 30 2022 | $48.54 | $0.78 | 62.2x | -93% |
| FY2022 Q3 | Sep 30 2022 | $70.55 | $0.76 | 92.8x | -89% |
| FY2022 Q2 | Jul 01 2022 | $72.19 | $0.67 | 107.7x | -87% |
| FY2022 Q1 | Apr 01 2022 | $80.48 | $0.58 | 138.8x | -83% |
| FY2021 Q4 | Dec 31 2021 | $91.30 | $0.49 | 186.3x | -78% |
| FY2021 Q3 | Oct 01 2021 | $127.79 | $0.46 | 277.8x | -67% |
| FY2021 Q2 | Jul 02 2021 | $144.73 | $0.42 | 344.6x | -59% |
| FY2021 Q1 | Apr 02 2021 | $105.76 | $0.22 | 471.7x | -44% |
| FY2020 Q4 | Jan 01 2021 | $79.22 | $0.12 | 653.6x | -22% |
| FY2020 Q3 | Oct 02 2020 | $56.43 | $0.19 | 295.1x | -65% |
| FY2020 Q2 | Jul 03 2020 | $61.62 | $0.16 | 382.3x | -54% |
| FY2020 Q1 | Apr 03 2020 | $29.15 | $0.27 | 109.2x | -87% |
| FY2019 Q4 | Jan 03 2020 | $34.38 | $0.30 | 114.6x | -86% |
| FY2019 Q3 | Sep 27 2019 | $25.99 | $0.18 | 144.4x | -83% |
| FY2019 Q2 | Jun 28 2019 | $29.38 | $0.16 | 183.6x | -78% |
| FY2019 Q1 | Mar 29 2019 | $34.19 | $0.12 | 284.9x | -66% |
| FY2018 Q4 | Dec 28 2018 | $31.26 | $0.10 | 312.6x | -63% |
| FY2018 Q3 | Sep 28 2018 | $48.00 | $0.08 | 625.8x | -25% |
| FY2018 Q2 | Jun 29 2018 | $31.00 | $0.08 | 404.2x | -52% |
| FY2018 Q1 | Mar 30 2018 | $14.80 | $0.01 | 1138.5x | +36% |
| FY2013 Q4 | Jan 03 2014 | $16.10 | $0.01 | 2515.6x | +201% |
| FY2012 Q2 | Jun 29 2012 | $7.77 | $0.00 | 5180.0x | +520% |
| FY2012 Q1 | Mar 30 2012 | $10.83 | $0.04 | 309.4x | -63% |
| FY2011 Q4 | Dec 30 2011 | $10.49 | $0.04 | 299.7x | -64% |
| FY2011 Q3 | Sep 30 2011 | $7.80 | $0.01 | 634.1x | -24% |
| FY2010 Q4 | Dec 31 2010 | $6.10 | $0.00 | 30500.0x | +3552% |
| FY2000 Q1 | Mar 31 2000 | $11.63 | $0.13 | 89.1x | -89% |
| FY1999 Q4 | Dec 31 1999 | $9.75 | $0.16 | 60.8x | -93% |
| FY1999 Q3 | Oct 01 1999 | $11.81 | $0.18 | 66.0x | -92% |
| FY1999 Q2 | Jul 02 1999 | $13.50 | $0.04 | 347.0x | -58% |
| FY1999 Q1 | Apr 02 1999 | $8.38 | $0.10 | 84.7x | -90% |
| FY1998 Q4 | Jan 01 1999 | $7.81 | $0.17 | 46.3x | -94% |
| FY1998 Q3 | Oct 02 1998 | $8.13 | $0.25 | 32.5x | -96% |
| FY1998 Q2 | Jul 03 1998 | $13.50 | $0.49 | 27.6x | -97% |
| FY1998 Q1 | Apr 03 1998 | $16.06 | $0.52 | 30.9x | -96% |
| FY1997 Q4 | Jan 02 1998 | $16.63 | $0.53 | 31.4x | -96% |
| FY1997 Q3 | Oct 03 1997 | $16.25 | $0.55 | 29.5x | -96% |
| FY1997 Q2 | Jul 04 1997 | $12.13 | $0.54 | 22.5x | -97% |
| FY1997 Q1 | Apr 04 1997 | $10.25 | $0.52 | 19.7x | -98% |
| FY1996 Q4 | Jan 03 1997 | $13.38 | $0.50 | 26.8x | -97% |
| FY1996 Q3 | Sep 27 1996 | $13.38 | $0.49 | 27.3x | -97% |
| FY1996 Q2 | Jun 28 1996 | $15.63 | $0.52 | 30.0x | -96% |
| FY1996 Q1 | Mar 29 1996 | $14.00 | $0.53 | 26.4x | -97% |
| FY1995 Q4 | Dec 29 1995 | $10.75 | $0.54 | 19.9x | -98% |
| FY1995 Q3 | Sep 29 1995 | $12.00 | $0.73 | 16.4x | -98% |
| FY1995 Q2 | Jun 30 1995 | $8.38 | $0.70 | 12.0x | -99% |
| FY1995 Q1 | Mar 31 1995 | $9.63 | $0.67 | 14.4x | -98% |
| FY1994 Q4 | Dec 31 1994 | $9.00 | $0.64 | 14.1x | -98% |
| FY1994 Q3 | Sep 30 1994 | $5.63 | $0.40 | 14.2x | -98% |
| FY1994 Q2 | - | $4.75 | $0.32 | 15.1x | -98% |
Average P/E for displayed period: 835.1x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
32+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
STAA — Frequently Asked Questions
Quick answers to the most common questions about buying STAA stock.
What is STAA's P/E ratio?
STAAR Surgical Company (STAA) trailing twelve-month P/E ratio is -18.0x, based on TTM diluted EPS of $-0.41. The 5-year average P/E is 198.2x and the historical range spans 62.2x to 653.6x.
Is STAA stock overvalued or undervalued?
STAA trades at -18.0x P/E, below its 5-year average of 198.2x. At the 0th percentile of its historical range (62.2x–653.6x), the stock is priced at a discount to its own history.
Is STAA stock expensive?
No, STAA is not expensive on a historical basis. The current P/E of -18.0x is below the 5-year average of 198.2x and sits at the 0th percentile of its valuation range.
What is STAA's historical P/E range?
Over the past 5 years, STAA's P/E ratio has ranged from 62.2x to 653.6x, with a median of 123.8x and an average of 198.2x. The current P/E of -18.0x places the stock at the 0th percentile of this range. Full historical data spans 1994–2024.
How does STAA's P/E compare to the S&P 500?
STAA trades at -18.0x P/E versus the S&P 500 median of 24.4x. The 174% discount to the market suggests lower growth expectations or perceived higher risk.
How does STAA's valuation compare to Healthcare peers?
STAAR Surgical Company P/E of -18.0x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is STAA's PEG ratio?
STAA PEG ratio is N/A, based on a P/E of -18.0x and EPS growth of -295.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is STAA's earnings yield?
STAA earnings yield is N/A, the inverse of its -18.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.